Vivos net loss widens to $2.02 million in 1H FY26; revenue rises to $72,468

• Vivos reported a net loss of $2.02 million for the six months ended June 30, 2026, widening from $1.48 million.
• Revenue rose to $72,468, up 73.58% year over year, driven by IsoPet therapies, IsoPet sales, and freight.
• Operating loss narrowed to $1.2 million from $1.54 million as operating expense fell to $1.19 million from $1.49 million.
• Non-operating results swung to a $815,013 loss from $58,096 income on a $847,628 loss on warrant exchanges.
• Business updates included FDA Early Feasibility IDE approval in July 2026 for a Mayo Clinic study, with 17 certified IsoPet clinics as of June 30.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037380), on August 12, 2026, and is solely responsible for the information contained therein.